

## CLAIMS

1. A method for treating an inflammatory disease accompanied by bone destruction, comprising the step of administering a vector encoding a protein or a nucleic acid which  
5 inhibits a signal transduction that is mediated by fibroblast growth factor-2 (FGF2)-FGF receptor 1-Ras-Raf-MAP kinase.
2. The method of Claim 1, wherein the vector is a negative single-stranded RNA viral vector.
3. The method of Claim 2, wherein the negative single-stranded RNA viral vector is a Sendai virus vector.
- 10 4. The method of Claim 1, wherein the protein that inhibits the signal transduction is selected from a group consisting of a soluble FGF receptor, Sprouty2, and Spred.
5. The method of Claim 1, wherein the disease is osteoarthritis.
6. A therapeutic composition for an inflammatory disease accompanied by bone destruction, comprising a vector encoding a protein or a nucleic acid which inhibits a signal transduction  
15 that is mediated by fibroblast growth factor-2 (FGF2)-FGF receptor 1-Ras-Raf-MAP kinase, and a pharmaceutically acceptable carrier.
7. The composition of Claim 6, wherein the vector is a negative single-stranded RNA viral vector.
8. The composition of Claim 7, wherein the negative single-stranded RNA viral vector is a  
20 Sendai virus vector.
9. The composition of Claim 6, wherein the protein that inhibits the signal transduction is selected from a group consisting of a soluble FGF receptor, Sprouty2, and Spred.
10. The composition of Claim 6, wherein the disease is osteoarthritis.